Register and share your invite link to earn from video plays and referrals.

Search results for 14B】「多摩川の景色を堪能! 拝島編」の巻
14B】「多摩川の景色を堪能! 拝島編」の巻 community
One keyword maps to one global community path.
Create community
People
Not Found
Tweets including 14B】「多摩川の景色を堪能! 拝島編」の巻
14B Miles Driven on Tesla FSD 📈
$1.14B+ TVL, an ATH for Robinhood Chain. More DeFi, more wallets, more to do.
0
241
1K
111
Forward to community
ORACLE EARNINGS • REVENUE: $19.3B VS $19.14B ESTIMATE • ADJ. EPS: $1.92 VS $1.74 ESTIMATE • CLOUD REVENUE: $11.6B VS $11.44B ESTIMATE • FY REVENUE GUIDANCE: ≥$90B VS $89.76B ESTIMATE • FY ADJ. EPS GUIDANCE: $8.10 VS $8.07 ESTIMATE • Q2 REVENUE GROWTH: 30%-34% • Q2 CLOUD REVENUE GROWTH: 65%-71% IN USD • AI CLOUD CONTRACTS: >$30B BOOKED IN Q1 • REMAINING PERFORMANCE OBLIGATION: $664B • DATACENTER CAPACITY: 850MW ADDED IN Q1 • CAPITAL RAISE: NO INCREMENTAL IMPACT ON PLANS TO RAISE CAPITAL
Show more
$IREN founders award themselves $1.14B+ of stock based compensation. Vesting over 4 years timeframe. This is amid their active $6,000,000,000 ATM. I’m not going to say anything but I think it speaks for itself.
Show more
0
151
1.1K
46
Forward to community
Visa ($V) beat Q4 estimates with $3.48 EPS on $12.14B in revenue. CEO Ryan McInerney called 2026 a “milestone year,” with full-year revenue hitting a record $46B, up 15%.
Boston Scientific Q3 2026 Earnings - Net Sales: $5.14B (est $5.05B) - Adjusted EPS: 73c (est 73c) - Sees FY Adjusted EPS: $3.16 To $3.18 (est $3.23)
THERMO FISHER SCIENTIFIC $TMO Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $12.14B (Est. $11.95B) 🟢; +9% YoY 🔹 Adj. EPS: $6.68 (Est. $6.40) 🟢; +15% YoY 🔹 Organic Revenue Growth: +6% Other Q3 Metrics: 🔹 Adj. Oper Income: $2.97B (Est. $2.87B) 🟢 🔹 Adj. Net Income: $2.48B (Est. $2.38B) 🟢 🔹 Adj. Oper Margin: 24.5%; +120 bps YoY 🔹 GAAP Oper Margin: 18.6%; +120 bps YoY 🔹 Free Cash Flow: $2.12B; vs $1.84B LY Segment Revenue: 🔹 Life Sciences Solutions: $2.72B; vs $2.59B LY 🔹 Analytical Instruments: $2.00B; vs $1.89B LY 🔹 Specialty Diagnostics: $1.10B; vs $1.17B LY 🔹 Lab Products & Biopharma: $6.86B; vs $5.97B LY Key Updates: 🔹 GAAP EPS: $4.64; +9% YoY 🔹 Completed our previously announced divestiture of our microbiology business 🔸 Cost of revenues adjustments: $0.02/share 🔸 Selling, general and administrative expenses adjustments: -$0.06/share 🔸 Restructuring and other costs: $0.54/share 🔸 Amortization of acquisition-related intangible assets: $1.40/share 🔸 Other income/expense adjustments: $0.04/share 🔸 Income taxes adjustments: $0.07/share 🔸 Equity in earnings/losses of unconsolidated entities: $0.02/share Comments: 🔸 “Looking ahead, we’re well positioned to deliver an excellent 2026 as we continue to drive long-term value creation for all of our stakeholders and build an even brighter future for our company.”
Show more
$IREN debt stack is maturing in real time • $25-30B CapEx forecast • 14B cash + committed financing/prepayments • Ability to debt-finance finished builds
COMCAST Q3 EARNINGS: - ADJUSTED EPS: $1.07 (EST 98C) - REVENUE: $29.30B (EST $29.14B) - PEACOCK REVENUE: $1.82B (EST $1.88B) - PEACOCK ADJUSTED EBITDA: $261M (EST $183.9M) - DOMESTIC WIRELESS LINES CHANGE: 368,000 (EST 392,375)
Show more